Sanders Challenges Trump’s Drug Price Order
President Trump’s latest executive order, aiming to align U.S. prescription drug prices with those of other developed nations, mirrors a previously blocked attempt and faces similar legal challenges. Senators Sanders and Wyden, along with Representative Khanna, argue that legislative action, rather than unilateral executive orders, is the only viable path to meaningful price reform. They cite the likelihood of pharmaceutical industry legal challenges and propose bipartisan legislation to achieve comparable drug pricing. This approach contrasts with Trump’s past actions, including delaying Medicare price negotiations.
John Q. Hosedrinker